In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Grandfather, 3-month-old granddaughter dead after violent dog attack Opinion: Why Marjorie ...

However, Recursion’s revenue fell short, reaching only $5.18 million compared to the expected $16.95 million. In another development, Recursion announced the registration of 7.1 million shares for ...

Shareholders of Noble Corporation plc (Symbol: NE) looking to boost their income beyond the stock's 7.1% annualized dividend yield can sell the January 2027 covered call at the $40 strike and collect ...

If you're looking for web links only in Google Search results, create a custom search shortcut for your browser. Peter is a writer and editor for the CNET How-To team. He has been covering technology, ...

Notable: Seattle is up to 54% to earn the No. 1 seed after beating the Panthers on Sunday, according to The Athletic's playoff predictor. If they beat the Niners on Saturday night, they'll win the No.